Last month, Hybridyne Imaging Technologies, Inc., Toronto, and the U.S. Department of Energy’s Brookhaven National Laboratory (BNL) demonstrated ProxiScan, a new prostate imaging technology, at WBTshowcase.
The team was one of 90 selected to present their device at the event, which highlights emerging technologies for venture capital investors, federal agencies, and licensees.
ProxiScan is a high-resolution imaging technology for prostate cancer. The device uses a cadmium zinc telluride (CZT)-based compact gamma camera that was developed with BNL scientists.
The CZT-based gamma camera is small enough for trans-rectal prostate cancer diagnosis after the patient is injected with a tracer radiopharmaceutical. Using the high-resolution CZT detector with its miniaturized electronics, the working distance between the gamma camera and the prostate gland is minimized. That shorter distance allows urologists to obtain better images with a smaller amount of injected radioactive tracer, compared to conventional nuclear medical systems.
According to Terry Lall, Hybridyne’s president and CEO, ProxiScan can detect prostate tumors almost 10 times smaller than conventional gamma cameras. “It delivers high performance in a small package at a much lower cost than conventional nuclear medical instruments,” he said in a post-showcase press release.
Visit BNL or Hybridyne for more information.
(Source: Press Release)
